top of page
ASG Receives U.S. FDA IND Approval to Initiate Phase 1 Clinical Trial of the Lead Drug Beta1 for Male Erectile Dysfunction
ASG received Investigational New Drug (IND) application clearance from the U.S. Food and Drug Administration (FDA). Beta1 is currently the only inhaled investigational therapy for male erectile dysfunction to have received such approval and prepared to enter clinical trial
ASG Announces the Completion of pre-IND meeting with FDA for Lead Drug Beta 1 , Receiving Encouraging Feedback
TAIPEI, Feb. 26, 2025 -- Asia Scientific Global (ASG), a company specializing in the research and development of novel inhaled novel...
ASG Pioneers Development of Novel Inhaled Drugs and Accelerates R&D Progress
TAIPEI, June 5, 2024 / Asia Scientific Global (ASG), a leader in the research and development of novel inhaled drugs, has set up a...
bottom of page